---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-034684"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2023-07-17T23:59:59+00:00"
generated_at: "2026-06-13T07:47:18.495854+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Phase 3 acoramidis hits primary endpoint in ATTR-CM; NDA planned by year-end 2023

## Summary
- Primary endpoint met with Win Ratio 1.8 (p<0.0001); 81% on-treatment survival vs 74% placebo.
- 50% relative risk reduction (p<0.0001) in frequency of cardiovascular-related hospitalization.
- All secondary endpoints (NT-proBNP, KCCQ, 6-min walk) statistically significant at 30 months (p<0.0001).
- No safety signals identified; NDA submission to FDA targeted by end of 2023.
- Exploratory analysis suggests 42% greater increase in serum TTR vs tafamidis; 92% improvement in median NT-proBNP.

## SEC filing metadata
- accession: 0001140361-23-034684
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2023-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036123034684/0001140361-23-034684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036123034684/brhc20055953_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-034684
- JSON: https://secwatch.observer/filing/0001140361-23-034684.json
- Plain text: https://secwatch.observer/filing/0001140361-23-034684.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.